Trust Asset Management LLC Takes Position in Hologic, Inc. (NASDAQ:HOLX)

Trust Asset Management LLC acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,853 shares of the medical equipment provider’s stock, valued at approximately $204,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of HOLX. McGlone Suttner Wealth Management Inc. bought a new position in shares of Hologic during the fourth quarter valued at about $27,000. Venturi Wealth Management LLC bought a new position in shares of Hologic during the third quarter valued at about $29,000. NBC Securities Inc. purchased a new stake in shares of Hologic during the third quarter worth about $33,000. Deseret Mutual Benefit Administrators boosted its holdings in shares of Hologic by 42.2% during the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 155 shares during the period. Finally, Massmutual Trust Co. FSB ADV boosted its holdings in shares of Hologic by 69.4% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 227 shares during the period. 94.73% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on HOLX. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a report on Wednesday, April 10th. UBS Group increased their target price on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Friday, February 2nd. StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Finally, Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and increased their target price for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Hologic currently has an average rating of “Hold” and an average target price of $87.00.

Hologic Stock Down 1.3 %

Shares of NASDAQ HOLX traded down $1.00 on Thursday, reaching $75.71. 1,190,936 shares of the company’s stock traded hands, compared to its average volume of 1,779,627. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $87.88. The business’s 50 day simple moving average is $75.98 and its two-hundred day simple moving average is $72.74. The company has a market cap of $17.77 billion, a price-to-earnings ratio of 35.88, a price-to-earnings-growth ratio of 2.61 and a beta of 1.00. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $989.32 million. During the same quarter last year, the firm earned $1.07 earnings per share. The business’s revenue for the quarter was down 5.7% on a year-over-year basis. As a group, equities research analysts forecast that Hologic, Inc. will post 4.01 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In related news, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the sale, the chief financial officer now owns 103,916 shares of the company’s stock, valued at $7,793,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the sale, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,846 shares of company stock valued at $2,473,443. Corporate insiders own 1.75% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.